about
Advances in targeting signal transduction pathwaysTP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence.Xenohormetic and anti-aging activity of secoiridoid polyphenols present in extra virgin olive oil: a new family of gerosuppressant agentsDeregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention.TOR-centric view on insulin resistance and diabetic complications: perspective for endocrinologists and gerontologists.Selective anti-cancer agents as anti-aging drugsPotential anti-aging agents suppress the level of constitutive mTOR- and DNA damage- signalingMetformin and the ATM DNA damage response (DDR): accelerating the onset of stress-induced senescence to boost protection against cancerMetformin: multi-faceted protection against cancer.Phenolic secoiridoids in extra virgin olive oil impede fibrogenic and oncogenic epithelial-to-mesenchymal transition: extra virgin olive oil as a source of novel antiaging phytochemicals.Metabolomic fingerprint reveals that metformin impairs one-carbon metabolism in a manner similar to the antifolate class of chemotherapy drugs.The mitochondria-targeted antioxidant SkQ1 but not N-acetylcysteine reverses aging-related biomarkers in rats.Metformin limits the tumourigenicity of iPS cells without affecting their pluripotency.Metformin for cancer and aging prevention: is it a time to make the long story short?Answering the ultimate question "what is the proximal cause of aging?"Mechanistic or mammalian target of rapamycin (mTOR) may determine robustness in young male mice at the cost of accelerated aging.Common drugs and treatments for cancer and age-related diseases: revitalizing answers to NCI's provocative questions.One-carbon metabolism: an aging-cancer crossroad for the gerosuppressant metforminAccelerated geroncogenesis in hereditary breast-ovarian cancer syndromeRepositioning chloroquine and metformin to eliminate cancer stem cell traits in pre-malignant lesions.M(o)TOR of aging: MTOR as a universal molecular hypothalamusDietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metforminIn search for geroprotectors: in silico screening and in vitro validation of signalome-level mimetics of young healthy state.Mitochondrial dysfunction: a basic mechanism in inflammation-related non-communicable diseases and therapeutic opportunities.Chemokine ligand 2 and paraoxonase-1 in non-alcoholic fatty liver disease: The search for alternative causative factors.Metformin: A Hopeful Promise in Aging Research.Ser2481-autophosphorylated mTOR colocalizes with chromosomal passenger proteins during mammalian cell cytokinesis.Ubiquitous transgenic overexpression of C-C chemokine ligand 2: a model to assess the combined effect of high energy intake and continuous low-grade inflammation.Metformin is synthetically lethal with glucose withdrawal in cancer cells.PPARs in Regulation of Paraoxonases: Control of Oxidative Stress and Inflammation Pathways.Rejuvenating regeneration: metformin activates endogenous adult stem cells.Metformin targets histone acetylation in cancer-prone epithelial cells.
P2860
Q27686983-129977BE-1861-4B3F-A97C-219BF79036FAQ27851687-6A135A73-8AC0-4A51-A450-ADBB3D44169FQ28395443-5ACC932C-3687-4520-B65A-2616B52F5CAFQ34103963-68AC5209-17D6-4BD5-8B61-A73072A250ECQ34391710-3D5BD902-3F95-4683-B540-54AEEBDFEC8AQ34392470-D183D4F8-C8BF-40A5-82A6-4284EB335575Q34567724-78289273-57DD-48F9-8B4F-5C1A7C172F6AQ35645149-CA3961B2-A29E-40D8-B535-E2D4193130E1Q35764409-B30C16E4-621D-4D8B-9DF0-DB2573DF155CQ35770306-0A459D0F-A5EC-4E1C-99B4-2633E8A48C75Q36209145-1AD10DE3-3B90-494D-8E54-48EAA15C2413Q36455187-8771A9E2-8B1C-4062-9350-2254F2E2D9EBQ36460656-9784E819-9591-4D0E-AB5E-E38D28716D48Q36545393-463E62D4-749F-4F78-90C5-4EFB393905C4Q36736351-41534E5D-E0C0-48C1-98CA-70DE440BD770Q36736362-A2E96BDF-2FCF-4C4D-9B3E-B91676271EB6Q36926148-3E9F86C4-B94E-458C-8C81-201A0763708FQ37001540-67F1FE0D-6D45-4B89-BCF1-DFE90235D334Q37022075-3C35C64D-6276-43C0-8D3D-08EEECB7B0D6Q37091483-4894BFC8-0ACE-4551-87B7-894EF0CD5882Q37152775-C2656779-3372-447D-A088-6B8BAF0F7A4DQ37299288-C66C4E33-461F-4B41-9888-48FA9D3DDC9AQ37361055-2E612053-4321-4B0D-A2B3-CE2338D3BA15Q38093566-E1746F53-22BA-4EE2-B7EC-FD882BA4D4A9Q38381079-17EDB58F-443B-438D-9820-9E27020DCB85Q38756907-FCB2182D-3D89-4A5B-8F8E-977B7113D69DQ39253995-BD90BCE3-76C5-4A94-82B9-4BD282351DE3Q39266499-DFEC8029-6B43-4032-9D2B-2C0D88713720Q39312255-41202FE3-B3EC-4969-9E49-66DB1C75BEB2Q40793611-E7133B1F-70EB-4E5F-BDAA-1F9651B0EC92Q42410143-01509ADA-96B5-47F9-BBD2-87FF7B3291B2Q42983569-46965E56-B74F-4C56-932F-A7E6272AE4A7
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Gerosuppressant metformin: less is more
@ast
Gerosuppressant metformin: less is more
@en
type
label
Gerosuppressant metformin: less is more
@ast
Gerosuppressant metformin: less is more
@en
prefLabel
Gerosuppressant metformin: less is more
@ast
Gerosuppressant metformin: less is more
@en
P2093
P2860
P356
P1433
P1476
Gerosuppressant metformin: less is more
@en
P2093
Alejandro Vazquez-Martin
Cristina Oliveras-Ferraros
Javier A Menendez
Jorge Joven
Luciano Vellon
Sílvia Cufí
P2860
P304
P356
10.18632/AGING.100316
P577
2011-04-01T00:00:00Z